As pet owners, we dread the day our companions show signs of illness, but a vet has explained everything you need to know.

This important study provides solid evidence to support the anti-tumor potential of citalopram, originally an anti-depression drug, in hepatocellular carcinoma (HCC). In addition to their previous ...

Chimeric antigen receptor-T (CAR-T) cell therapy, initially successful in hematologic malignancies, presents a promising avenue for treating solid tumors, including CRC. This review explores the ...

When a child develops a brain tumor, early diagnosis is essential. Alan Cohen, M.D., director of pediatric neurosurgery at Johns Hopkins Children’s Center, shares the most common signs and symptoms ...

to target a cell-surface receptor called DR5 (death receptor 5) that many tumor cells have. When activated, DR5 can trigger the death of these cells by a self-destruct process called apoptosis.

Scientists identified the tiny species of cat from a fossilized jawbone, which could date back as far as 300,000 years ago. When you purchase through links on our site, we may earn an affiliate ...

According to precedent and due to his status, Yoon will probably be assigned a solitary cell, likely bigger and better appointed than the standard 6.56 square metre (71 square feet) single cells.

iPSC-derived cell therapies have the potential to transform cancer care by offering scalable, 'off-the-shelf' treatment options. However, bringing efficacious therapies to patients requires robust ...

Get Instant Summarized Text (Gist) Research has uncovered why tumor cells die differently after radiotherapy, revealing that DNA repair pathways dictate the mode of cell death. When homologous ...

German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany. 3Department of Functional Neuroanatomy, Institute for Anatomy and Cell Biology, Heidelberg University, ...

Collaboration leverages Ginkgo's cell engineering and screening platform to enhance the potency and persistence of Universal Cells' iPSC-derived immune cell therapeutics BOSTON, Jan. 13, 2025 ...